Table 1. Demographical and clinical features of the study cohort.
ID | Age (y) | Disease duration (y) | Type of electrode | Most affected side | Total LEDD (mg) | D-ag LEDD (mg) | UPDRS-III off | UPDRS-III on | ICB state | Type of active ICB |
---|---|---|---|---|---|---|---|---|---|---|
01 | 60 | 8 | Medtronic 3389 | L | 970 | 320 | 28 | 8 | Active ICB | Compulsive shopping, hypersexuality |
02 | 60 | 15 | DB-2202 | R | 1563 | 315 | 50 | 30 | Past ICB | |
03 | 60 | 6 | Medtronic 3389 | L | 800 | 0 | 48 | 14 | Past ICB | |
04 | 60 | 13 | DB-2202 | L | 1403 | 280 | 77 | 27 | past ICB | |
05 | 47 | 16 | DB-2202 | R | 865 | 0 | 71 | 37 | past ICB | |
06 | 53 | 7 | DB-2202 | L | 635 | 160 | 38 | 25 | Active ICB | Hypersexuality, compulsive eating, punding |
07 | 55 | 16 | Medtronic 3389 | R | 1810 | 360 | 51 | 19 | Never ICB | |
08 | 65 | 15 | Medtronic 3389 | L | 666 | 0 | 57 | 34 | Never ICB | |
09 | 52 | 7 | DB-2202 | L | 1152 | 180 | 18 | 1 | Active ICB | Hypersexuality, compulsive shopping |
10 | 66 | 9 | DB-2202 | R | 1124 | 360 | 52 | 30 | Never ICB | |
11 | 65 | 5 | Medtronic 3389 | R | 995 | 320 | 34 | 16 | Never ICB | |
12 | 48 | 7 | DB-2202 | R | 1180 | 0 | 45 | 34 | Active ICB | Pathological gambling |
13 | 61 | 10 | DB-2202 | R | 500 | 0 | 33 | 12 | Past ICB | |
14 | 51 | 12 | DB-2202 | L | 1020 | 320 | 27 | 13 | Active ICB | Hypersexuality |
15 | 56 | 6 | DB-2202 | R | 1380 | 480 | 48 | 19 | Past ICB | |
16 | 66 | 6 | Bsci octode | L | 580 | 0 | 17 | 11 | Never ICB | |
17 | 67 | 7 | AB-6170 | L | 820 | 320 | 17 | 5 | Never ICB | |
18 | 62 | 6 | DB-2202 | R | 1082 | 300 | 42 | 13 | Never ICB | |
19 | 64 | 12 | DB-2202 | L | 160 | 160 | 52 | 21 | Active ICB | Compulsive shopping |
20 | 63 | 10 | DB-2202 | R | 780 | 80 | 40 | 17 | Never ICB | |
21 | 63 | 10 | AB-6170 | R | 1800 | 375 | 41 | 11 | Past ICB | |
22 | 52 | 11 | DB-2202 | L | 1470 | 160 | 54 | 27 | Never ICB | |
23 | 63 | 10 | DB-2202 | R | 1275 | 300 | 29 | 10 | Never ICB |
Abbreviations: D-Ag, dopamine-agonists; F, female; ICB, impulsive compulsive behavior disorders; L, left; LEDD, levodopa equivalent daily dose; M, male; R, right; y, years; UPDRS-III, Unified Parkinson’s disease rating scale; Implanted leads, Medtronic 3389, (Medtronic, Minneapolis, USA) four 0.5-mm spaced contacts of 1.5-mm length with platinum-iridium cylindrical surfaces; DB-2202, directional leads from Boston Scientific with three segmented contacts on the middle levels (Boston Scientific, USA); Bsci octode, octopolar non directional leads from Boston Scientific; AB-6170, directional leads from St. Jude Medical with three segmented contacts on the middle levels (model 6170, Abbott Neuromodulation, Austin, TX, USA).